Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boniva Gets A Second, Truncated 30-Month Stay

This article was originally published in The Pink Sheet Daily

Executive Summary

Orchid's revised patent certification against the osteoporosis drug ibandronate allows Roche to block approval until March 2012.

You may also be interested in...



Baxter Seeks Unusual Second 30-Month Stay On Generic Version Of Its Anesthetic Suprane

A redesign of the proposed generic and changes to the Paragraph IV certification could give the brand an additional six-month hold on approval of the ANDA.

Baxter Seeks Unusual Second 30-Month Stay On Generic Version Of Its Anesthetic Suprane

A redesign of the proposed generic and changes to the Paragraph IV certification could give the brand an additional six-month hold on approval of the ANDA.

Court Rules Apotex, Cobalt Infringe Roche's Boniva Patent

A New Jersey district court judge trounces the generic manufacturers' claim that the salt of the drug's active ingredient is not physiologically active.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel